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Background: Microglia reactivity is a hallmark of neurodegenerative diseases. We have previously identified activated
microglia/macrophage whey acidic protein (AMWAP) as a counter-regulator of pro-inflammatory response. Here, we
studied its mechanisms of action with a focus on toll-like receptor (TLR) and nuclear factor κB (NFκB) signaling.
Methods: Recombinant AMWAP was produced in Escherichia coli and HEK293 EBNA cells and purified by affinity
chromatography. AMWAP uptake was identified by fluorescent labeling, and pro-inflammatory microglia markers
were measured by qRT-PCR after stimulation with TLR ligands. NFκB pathway proteins were assessed by
immunocytochemistry, Western blot, and immunoprecipitation. A 20S proteasome activity assay was used to
investigate the anti-peptidase activity of AMWAP. Microglial neurotoxicity was estimated by nitrite measurement
and quantification of caspase 3/7 levels in 661W photoreceptors cultured in the presence of microglia-conditioned
medium. Microglial proliferation was investigated using flow cytometry, and their phagocytosis was monitored by the
uptake of 661W photoreceptor debris.
Results: AMWAP was secreted from lipopolysaccharide (LPS)-activated microglia and recombinant AMWAP reduced
gene transcription of IL6, iNOS, CCL2, CASP11, and TNFα in BV-2 microglia treated with LPS as TLR4 ligand. This effect
was replicated with murine embryonic stem cell-derived microglia (ESdM) and primary brain microglia. AMWAP also
diminished pro-inflammatory markers in microglia activated with the TLR2 ligand zymosan but had no effects on IL6,
iNOS, and CCL2 transcription in cells treated with CpG oligodeoxynucleotides as TLR9 ligand. Microglial uptake of
AMWAP effectively inhibited TLR4-dependent NFκB activation by preventing IRAK-1 and IκBα proteolysis. No inhibition
of IκBα phosphorylation or ubiquitination and no influence on overall 20S proteasome activity were observed.
Functionally, both microglial nitric oxide (NO) secretion and 661W photoreceptor apoptosis were significantly reduced
after AMWAP treatment. AMWAP promoted the filopodia formation of microglia and increased the phagocytic uptake
of apoptotic 661W photoreceptor cells.
Conclusions: AMWAP is secreted from reactive microglia and acts in a paracrine fashion to counter-balance
TLR2/TLR4-induced reactivity through NFκB inhibition. AMWAP also induces a neuroprotective microglial phenotype
with reduced neurotoxicity and increased phagocytosis. We therefore hypothesize that anti-inflammatory whey acidic
proteins could have a therapeutic potential in neurodegenerative diseases of the brain and the retina.
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Microglial cells are the resident macrophages of the cen-
tral nervous system (CNS), including the retina, and play a
pivotal role in innate immune responses and regulation of
homeostasis in the healthy and degenerating CNS [1,2].
Despite being cells of the mononuclear phagocyte lineage,
their CNS-specific location and morphology clearly distin-
guishes them from other macrophage populations [3].
While actively scanning the microenvironment with their
long protrusions [4,5], loss of inhibitory signals and the
recognition of damage-associated molecular patterns from
degenerating neurons lead to the activation of microglia
[6-8]. Therefore, reactive microgliosis is a common
hallmark of various neurodegenerative diseases including
Alzheimer’s disease [9], Parkinson’s disease [10], multiple
sclerosis [11], inherited retinal degenerations [12], and
several other retinal diseases [13].
We have previously identified activated microglia/macro-
phage whey acidic protein (AMWAP) as a novel marker of
retinal microglial reactivity that is broadly upregulated in
several prototypic mouse models of retinal degeneration
including retinoschisin-deficient and Fam161a mutant ani-
mals [14,15]. AMWAP consists of a 76 aa polypeptide with
a cleavable N-terminal 19 aa signal sequence for cellular
export and a single 57 aa four-disulfide core domain that is
characteristic for all whey acidic proteins [16]. AMWAP
overexpression in microglia elicits several immunoregula-
tory effects including reduction of both pro-inflammatory
marker gene expression and migration [14].
The whey acidic protein family is characterized by a
highly conserved whey acidic protein domain which is
named after the most abundantly expressed protein WAP
from rodent milk [17]. AMWAP is closely related to
secretory leukocyte protease inhibitor (SLPI), which is the
best studied whey acidic protein [18,19]. In contrast to
AMWAP, SLPI contains two consecutive WAP domains
and is produced at mucosal surfaces as well as by neutro-
phils and macrophages [20]. SLPI was recently identified
as a biomarker for amyotrophic lateral sclerosis [21] and
its application has beneficial therapeutic effects after spinal
cord injury and optic nerve damage in rodents [22-24].
Toll-like receptor (TLR)-mediated NFκB signaling is a
major pathway of pro-inflammatory microglia reactivity
that may contribute to chronic neuroinflammation
[25,26]. NFκB is tightly regulated via inhibitory κB (IκB)
proteins (predominantly IκBα) which mask the nuclear
translocation signal of NFκB [27]. TLR ligands including
damage-associated molecular patterns from apoptotic
retinal neurons [28] and bacterial lipopolysaccharide in-
duce rapid phosphorylation of IκBα by IκB kinase (IKK)
followed by ubiquitination and proteasomal degradation
within minutes [29,30]. Upon translocation to the nu-
cleus, NFκB rapidly activates the transcription of pro-
inflammatory genes. The whey acidic proteins SLPI andelafin both inhibit NFκB activation in monocytes by inter-
fering with degradation of IκBα and IRAK-1, an upstream
mediator of NFκB signaling [31,32].
In this study, we used microglial cells and several bio-
chemical and immunological assays to elucidate whether
AMWAP also influences NFκB signaling and thereby trig-




Escherichia coli 0111:B4 lipopolysaccharide (LPS), zymosan
from Saccharomyces cerevisiae, Z-Leu-Leu-Leu-al (MG-
132), and D-desthiobiotin were purchased from Sigma-
Aldrich (St. Louis, MO, USA). CpG oligodeoxynucleotides
were purchased from Invivogen (Toulouse, France). N-
Acetyl-Leu-Leu-Norleu-al (ALLN) was purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). Puromycin
dihydrochloride was purchased from Gold Biotechnology
(St. Louis, MO, USA).
Cell culture
BV-2 microglia were cultured in RPMI1640 with 5% fetal
calf serum (FCS) supplemented with 2 mM L-glutamine
and 195 nM β-mercaptoethanol at 37°C in a humidified
atmosphere of 5% CO2 as previously described [33]. BV-
2 cells were preincubated for 24 h with 10 μg/ml recom-
binant AMWAP or PBS as vehicle control, unless stated
otherwise. BV-2 cells were stimulated with 50 ng/ml
LPS, 50 μg/ml zymosan, or 4 μg/ml CpG oligodeoxynu-
cleotides. BV-2 cells were preincubated with the prote-
asome inhibitor ALLN (100 μg/ml) for 30 min before
LPS stimulation to allow for accumulation of phosphory-
lated proteins. Generation and culture conditions of em-
bryonic stem cell-derived microglia (ESdM) and mouse
brain microglia have been described previously [34,35].
ESdM and primary microglia were preincubated for 24 h
with 10 μg/ml recombinant AMWAP or PBS as vehicle
control and stimulated with 500 ng/ml and 50 ng/ml
LPS, respectively. 661W photoreceptor-like cells were a
kind gift from Prof. Muayyad Al-Ubaidi (Department of
Cell Biology, University of Oklahoma Health Sciences
Center, Oklahoma City, OK, USA), and the culture condi-
tions have been described elsewhere [36]. HEK293 EBNA
cells were cultured in DMEM low glucose with 1 mM
sodium pyruvate and 10% FCS. All media were supple-
mented with 1% penicillin/streptomycin.
Recombinant protein expression
Recombinant expression and purification of C-terminally
His-tagged AMWAP in E. coli was carried out as de-
scribed previously [14]. For eukaryotic expression of C-
terminally Strep(II)-tagged AMWAP, the AMWAP ORF
was amplified from BV-2 microglial cDNA with primers
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5′-cccctcgagaaagacaggagttttgcaga-3′ and subcloned into
the pCEP-Pu plasmid at restriction sites NheI and XhoI.
This plasmid includes the BM-40 signaling peptide which
leads to secretion and is then cleaved off from the recom-
binant protein. The clone was validated by DNA sequen-
cing. HEK293 EBNA cells were transfected with the
expression plasmid using the Turbofect™ reagent (Thermo
Scientific, Waltham, MA, USA). After 24 h, 3 μg/ml puro-
mycin was added to select for plasmid-positive cells. After
expansion of the cells, FCS-free supernatants containing
secreted AMWAP were collected every 48 h, centrifuged
for 7 min at 3,500 rpm at 4°C and 1 mM PMSF was added.
For affinity chromatography, a Strep-Tactin® Sepharose
(Iba Life Sciences, Goettingen, Germany) column was pre-
pared and the supernatant loaded onto and passed
through the column at a velocity of 0.25 ml/min at 4°C
using a peristaltic pump P-1 (GE Healthcare, Little Chal-
font, UK). Thereafter, the column was washed with PBS
(pH 7.8) and recombinant AMWAP eluted with PBS con-
taining 2.5 mM D-desthiobiotin. Protein-containing frac-
tions were identified using a NanoDrop 2000 (Thermo
Scientific), and protein concentration was determined by
Bradford assay (Roti®-Quant, Roth, Karlsruhe, Germany)
and BCA assay (Roti®-Quant universal, Roth). Recombinant
protein was then stored at −20°C until further use.
Generation of an AMWAP antiserum and Western blot
analysis
Rabbit antibodies were raised against an N-terminally
GST-tagged recombinant AMWAP peptide. The AMWAP
ORF was cloned into a pGEX-4-T1 vector system to ex-
press an N-terminally GST-tagged AMWAP protein in
prokaryotic cells. The AMWAP ORF was PCR amplified
from a plasmid that was described previously [14]. GST-
tagged AMWAP protein was expressed and purified as de-
scribed above. Immunization of rabbits, isolation of serum,
and affinity purification was performed by Davids Biotech-
nologie GmbH (Neutraubling, Germany). For extraction of
total cellular protein, BV-2 cells were lysed in cold RIPA
buffer (20 mM Na-phosphate buffer, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, and protease inhibitors) and in-
soluble debris was removed by centrifugation for 15 min at
13,200 rpm. Nuclear and cytosolic protein extraction was
carried out using the NE-PER kit (Thermo Scientific) ac-
cording to the manufacturer’s instructions. Serum-free
microglial supernatants were concentrated 50-fold using
Amicon® Ultra-4 centrifugal filter units with a molecular
weight cut-off at 3 kDa (Merck-Millipore, Billerica, MA,
USA). Protein concentrations were determined by Brad-
ford assay (Roti®-Quant, Roth). A 10 to 20 μg of protein
was separated by SDS-PAGE on 10% to 15% gels with
PageRuler pre-stained protein ladder (Thermo Scientific).
Proteins were then transferred to 0.45 μm nitrocellulosemembranes (Bio-Rad, Munich, Germany). After blocking
in TBS-T containing 5% nonfat dry milk or bovine serum
albumin, membranes were incubated with primary anti-
bodies against AMWAP, NFκB p65 (sc-372, Santa Cruz
Biotechnology), phosphorylated NFκB p65 (sc-33020, Santa
Cruz Biotechnology), IRAK-1 (sc-7883, Santa Cruz Biotech-
nology), IκBα (sc-371, Santa Cruz Biotechnology), phos-
phorylated IκBα (sc-101713, Santa Cruz Biotechnology),
ubiquitin (ab7780, Abcam, Cambridge, UK), actin (sc-1616,
Santa Cruz Biotechnology), or GAPDH (sc-48166, Santa
Cruz Biotechnology). Blots were then incubated with
secondary goat anti-rabbit IgG-HRP or rabbit anti-goat
IgG-HRP antibodies (sc-2004, sc-2768, Santa Cruz Bio-
technology). Enhanced chemiluminescence signals were
visualized and imaged with the MultiImage II system
(Alpha Innotech, Santa Clara, CA, USA). Total protein
visualization was done by Ponceau S staining.RNA isolation and reverse transcription
Total RNA was extracted from microglia cells according
to the manufacturer’s instructions using the NucleoSpin®
RNA Mini Kit (Macherey-Nagel, Dueren, Germany). RNA
was quantified spectrophotometrically using a NanoDrop
2000 (Thermo Scientific) and then stored at −80°C.
First-strand cDNA synthesis was performed with the
RevertAid™ H Minus First strand cDNA Synthesis Kit
(Thermo Scientific).Quantitative real-time RT-PCR
Amplifications of 50 ng cDNA were performed with an
ABI7900HT machine (Applied Biosystems, Carlsbad, CA,
USA) in 10 μl reaction mixtures containing 1× TaqMan
Universal PCR Master Mix (Applied Biosystems), 200 nM
of primers, and 0.125 μl of dual-labeled UPL probe (Roche
Applied Science, Basel, Switzerland). The reaction param-
eters were as follows: 2 min 50°C hold, 30 min 60°C hold,
and 5 min 95°C hold, followed by 40 cycles of 20 s 94°C
melt and 1 min 60°C anneal/extension. Primer sequences
and UPL probe numbers were as follows: IL6, forward
primer 5′-gatggatgctaccaaactggat-3′, reverse primer 5′-
ccaggtagctatggtactccaga-3′, probe #6; iNOS, forward
primer 5′-ctttgccacggacgagac-3′, reverse primer 5′-
tcattgtactctgagggctga-3′, probe #13; CCL2, forward pri-
mer 5′-catccacgtgttggctca-3′, reverse primer 5′-gatcatc
ttgctggtgaatgagt-3′, probe #62; CASP11, forward pri-
mer 5′-gatcgggcaaccttgaca-3′, reverse primer 5′-tgagatt
cagttgcttgttgc-3′, probe #72; TNFα, forward primer 5′-
ctgtagcccacgtcgtagc-3′, reverse primer 5′-ttgagatccatgc
cgttg-3′, probe #78; ATP5B, forward primer 5′-ggcacaa
tgcaggaaagg-3′, reverse primer 5′-tcagcaggcacatagatagc
c-3′, probe #77. ATP5B expression was used as the
most stable reference gene. Measurements were per-
formed in triplicates, and results were analyzed with the
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ΔΔCt method for relative quantification.
Fluorescence labeling of recombinant AMWAP
Recombinant AMWAP was fluorescently labeled using
the Fluorescein-EX Protein Labeling Kit (Life Technolo-
gies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. This dye has a seven-atom spacer between
the succinimidyl ester group and the fluorophore to
minimize unwanted interaction between the fluorophore
and the labeled protein. After labeling, the protein solu-
tion was passed five times through an Amicon® Ultra-4
centrifugal filter unit with a molecular weight cut-off at
3 kDa (Merck-Millipore) at 4°C and extensively washed
with PBS to get rid of excess fluorescent dye.
Immunocytochemistry
BV-2 cells were seeded on glass cover slips and incu-
bated with 10 μg/ml fluorescently labeled AMWAP or
vehicle for different time spans prior to stimulation with
50 ng/ml LPS for 1 h. Cells were then fixed with 4% for-
maldehyde, washed with PBS, and incubated in blocking
buffer containing 10% goat serum and 0.3% Triton X-
100. Subsequently, cells were incubated with antibodies
against Iba1 or the p65 subunit of NFκB in a solution
containing 2.5% goat serum and 0.1% Triton X-100 for
1 h at room temperature. After 30-min incubation with
goat anti-rabbit Alexa-594 (A-11012, Life Technologies),
slides were washed with PBS and stained with 4′,6-diami-
dino-2-phenylindole (DAPI). Cover slips were mounted
with fluorescent mounting medium (Dako Cytomation,
Hamburg, Germany), and fluorescence photomicrographs
were taken with an AxioImager.M2 plus ApoTome2
microscope (Carl Zeiss, Oberkochen, Germany). ImageJ
software (National Institutes of Health, Bethesda, MD,
USA) was used to determine the ratio of nuclear to cyto-
solic NFκB p65 after quantifying pixel intensities of both
cellular compartments and subtracting background
fluorescence.
Immunoprecipitation
In a total volume of 200 μl, cytosolic extracts (200 μg of
protein), supplemented with 1× complete protease in-
hibitor mix (Roche Applied Science), were incubated
with 30 μl Protein A-sepharose® 4B (Sigma-Aldrich) for
60 min at 4°C and subsequently centrifuged for 10 min
at 2,000 g. The pre-cleared samples were then incubated
at 4°C overnight with 2 μg of anti-IκBα antibody (sc-371,
Santa Cruz Biotechnology). Thereafter, 30 μl fresh Protein
A-sepharose® 4B was added and the mixture was incu-
bated overnight at 4°C to allow for immunoprecipitation.
The beads were then pelleted by centrifugation at 2,000 g
and the pellet washed five times with PBS. Beads were
then incubated in SDS-PAGE sample buffer at 95°C for5 min and electrophoresed on a 10% SDS-PAGE. The
gel was blotted and the membrane incubated with an
anti-ubiquitin antibody at 4°C overnight followed by incu-
bation with secondary goat anti-rabbit IgG-HRP at room
temperature for 1 h. Enhanced chemiluminescence signals
were then visualized and imaged with the MultiImage II
system (Alpha Innotech).
20S proteasome activity assay
Trypsin-, chymotrypsin-, and caspase-like peptidase activ-
ities associated with the 20S proteasome were measured
using the Proteasome-Glo™ Assay System (Promega,
Madison, WI, USA). A 1 μg/ml of purified 20S prote-
asome (Enzo Life Sciences, Farmingdale, NY, USA) was
incubated at room temperature for 30 min with vehicle,
20 μg/ml AMWAP or 1 μM MG-132 peptidase inhibi-
tor positive control in a 96-well plate containing the
substrate for one specific peptidase. Luminescence was
then measured with an Infinite F200 Pro plate reader
(Tecan, Crailsheim, Germany). A blank reaction without
20S proteasome was used to determine background lu-
minescence associated with the vehicle and Proteasome-
Glo™ reagent. The values of the blank reactions were sub-
tracted from all experimental values. Relative luciferase
units (RLUs) correspond to the levels of peptidase activity.
Nitrite measurement
Nitric oxide concentrations were determined by meas-
urement of nitrite released into BV-2 culture superna-
tants using the Griess reagent system (Promega). Fifty
microliter cell culture supernatants from control, 50 ng/
ml LPS-, 10 μg/ml AMWAP-, or 50 ng/ml LPS + 10 μg/
ml AMWAP-treated BV-2 microglia were incubated
with 100 μl Griess reagent in each well of a translucent
96-well plate. After incubation for 30 min at room
temperature, absorbance was measured at 540 nm on an
Infinite F200 Pro plate reader (Tecan). Nitrite concen-
trations were calculated on the basis of a sodium nitrite
reference curve.
661W photoreceptor apoptosis assay
To investigate microglial neurotoxicity, 661W photorecep-
tor cells were incubated for 48 h with culture supernatants
from control, 50 ng/ml LPS-, 10 μg/ml AMWAP-, or
50 ng/ml LPS + 10 μg/ml AMWAP-treated BV-2 micro-
glia. Apoptotic cell death was determined using the
Caspase-Glo® 3/7 Assay (Promega). Cells were lysed and
incubated with a luminogenic caspase-3/7 substrate,
which contains the tetrapeptide sequence DEVD. After
incubation at room temperature for 1 h, the generated
luminescence was measured on an Infinite F200 Pro
plate reader (Tecan). A blank reaction without cells was
used to determine background luminescence associated
with the cell culture system and Caspase-Glo® 3/7 reagent.
Aslanidis et al. Journal of Neuroinflammation  (2015) 12:77 Page 5 of 14The values of the blank reactions were subtracted from all
experimental values. Negative control reactions were per-
formed to determine the basal caspase activity of 661W
cells. Relative luciferase units (RLUs) reflect the level of
apoptotic cell death.Phalloidin-TRITC staining
BV-2 cells were seeded on cover slips in six-well plates,
and attachment was allowed overnight. Cells were then
preincubated with 10 μg/ml AMWAP or vehicle for
24 h before incubation with 50 ng/ml LPS for 24 h.
Thereafter, cells were fixed with 4% formaldehyde,
permeabilized with 0.1% Triton X-100, and F-actin was
fluorescently labeled using 0.1 μg/ml Phalloidin-TRITC
(Sigma-Aldrich). Nuclei were stained using DAPI, and
the cover slips were mounted with fluorescent mounting
medium (Dako Cytomation). Photomicrographs were
taken with an AxioImager.M2 plus ApoTome2 micro-
scope (Carl Zeiss).
Proliferation assay
For carboxyfluorescein diacetate succinimidyl ester
(CFSE) proliferation assay, BV-2 microglia were labeled
with 5 μM CFSE (e-Bioscience, San Diego, CA, USA)
and cultured in a six-well plate. After 24 h of AMWAP
or vehicle pretreatment and subsequent 24 h of LPS
treatment, cells were stained with a fixable viability dye
(e-Bioscience) to exclude dead cells from the analysis.
The fluorescence intensity of CFSE-labeled BV-2 cells
was analyzed by flow cytometry on a FACS Canto II (BD
Biosciences, San Jose, CA, USA). Analysis of cell division
rate was performed using FlowJo software (Treestar Inc.,
Ashland, OR, USA).
Phagocytosis assay
661W photoreceptor cells were starved by serum
deprivation and harvested and fluorescently labeled
using CellTracker CM-DiI (Invitrogen, Carlsbad, CA,
USA). For phagocytosis assay, BV-2 cells were seeded on
cover slips in six-well plates and attachment was allowed
overnight. After pretreatment with 10 μg/ml AMWAP
for 24 h and subsequent stimulation with 50 ng/ml LPS
for 24 h, 500 μl-stained apoptotic 661W cell suspension
was added for 6 h. After extensive washing with PBS to
get rid of remaining extracellular 661W debris, cells
were fixed and nuclei were stained with DAPI. Fluores-
cence micrographs with constant exposure times were
taken with an AxioImager.M2 plus ApoTome2 micro-
scope (Carl Zeiss). ImageJ software (National Institutes
of Health) was used to determine the ratio of phagocy-
tosed apoptotic photoreceptor fragments (background-
corrected red signal) relative to the total microglia cell
number (background-corrected DAPI signal).Statistical analysis
Quantitative real-time RT-PCR data were analyzed with
the ΔΔCt method using an unpaired Student’s t-test. As-
says for NFκB localization, 20S proteasome inhibition,
nitrite secretion, caspase 3/7, and phagocytic activity
were analyzed with a Mann–Whitney U-test. P < 0.05
was considered statistically significant.
Results
AMWAP is secreted from reactive microglia
To elucidate whether AMWAP is secreted from reactive
microglia, we treated BV-2 microglial cells with 50 ng/
ml LPS for 48 h and analyzed AMWAP in cell culture
supernatants and cellular extracts using a newly gener-
ated anti-AMWAP antibody. The Western blot analysis
detected a single specific band at approximately 12 kDa
in culture supernatants of LPS-activated BV-2 microglia
but not in unstimulated cells (Figure 1A). Anti-GAPDH
immunoblotting and Ponceau S staining served as load-
ing controls for intracellular and secreted proteins. Thus,
we conclude that AMWAP can be actively secreted from
microglia when stimulated with a pro-inflammatory trig-
ger such as the TLR4 ligand LPS.
To analyze the paracrine effects of AMWAP, we next
carried out recombinant expression of C-terminally His-
tagged and C-terminally Strep(II)-tagged AMWAP using
E. coli and HEK293 EBNA cells, respectively. After purifi-
cation by affinity chromatography, recombinant proteins
were immunoblotted and detected with the anti-AMWAP
antibody. Specific single bands were present at approxi-
mately 11 kDa for AMWAP-His and approximately
13 kDa for AMWAP-Strep(II) (Figure 1B). These recom-
binant AMWAP proteins were then used for all further
functional studies.
AMWAP reduces the TLR-mediated pro-inflammatory
microglia response through NFκB inhibition
Next, we investigated whether exogenous stimulation
with AMWAP influences pro-inflammatory microglia
reactivity in BV-2 cells. We tested the effects of different
AMWAP concentrations ranging from 0.1 to 10 μg/ml
on TLR4/LPS-induced mRNA expression of the pro-
inflammatory mediators IL6, iNOS, CCL2, and CASP11
using quantitative real-time RT-PCR. These specific
transcripts were selected as surrogate markers for the
key microglia pathways pro-inflammatory cytokines, rad-
ical production, chemotaxis, and inflammatory caspases.
AMWAP strongly and dose-dependently suppressed
mRNA levels of IL6 and iNOS and had a less pronounced
but significant effect on CCL2 and CASP11 gene expres-
sion (Figure 2).
Since BV-2 is a microglial cell line, we then validated
these findings in embryonic stem cell-derived microglia
(ESdM), a recently established model system which exhibits
Figure 1 AMWAP is secreted from reactive BV-2 microglia. (A) BV-2 microglial cells were treated with 50 ng/ml LPS for 48 h before obtaining
cellular protein lysates (L) as well as concentrated culture supernatants (S). Anti-AMWAP immunoblot analysis revealed a band of approximately
12 kDa only present in the supernatant of LPS-activated microglia. GAPDH and Ponceau S served as loading controls. (B) Anti-AMWAP immunoblot
analysis of recombinantly expressed and purified AMWAP from E. coli (AMWAP-His) and HEK293 EBNA cells (AMWAP-Strep(II)) shows single bands at
approximately 11 to 13 kDa.
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pretreated with 10 μg/ml AMWAP showed significantly
reduced mRNA expression of the pro-inflammatory
mediators IL6, iNOS, CCL2, CASP11, and TNFα after
LPS activation (Figure 3A-E). These results were also fullyFigure 2 AMWAP reduces pro-inflammatory marker gene transcription in
of recombinant AMWAP for 24 h before further stimulation with 50 ng/m
(A), iNOS (B), CCL2 (C), and CASP11 (D) were determined by quantitative
triplicate) with *P < 0.05, **P < 0.01, ***P < 0.001 for AMWAP + LPS- vs. LPreplicated in primary mouse brain microglia (Figure 3F-J),
indicating that BV-2 microglia are a suitable model to
study the effects of AMWAP on microglia.
We next investigated a potential anti-inflammatory effect
of AMWAP on microglial cells that were activated withBV-2 microglia. BV-2 cells were treated with various concentrations
l LPS for 12 h. Transcript levels of the pro-inflammatory markers IL6
real-time PCR. Data show mean ± SD (n = 3/group, measured in
S-treated cells. PBS served as vehicle control.
Figure 3 AMWAP reduces TLR4-mediated pro-inflammatory gene transcription in embryonic stem cell-derived microglia and primary brain microglia.
(A-E) Embryonic stem cell-derived microglia (ESdM) were treated with 10 μg/ml of recombinant AMWAP for 24 h before stimulation with 500 ng/ml
LPS for further 24 h. (F-J) Primary brain microglia were treated with 10 μg/ml of recombinant AMWAP for 24 h before stimulation with 50 ng/ml LPS
for further 24 h. mRNA expression of the pro-inflammatory marker transcripts IL6 (A, F), iNOS (B, G) CCL2 (C, H), CASP11 (D, I), and TNFα (E, J) was
determined by quantitative real-time RT-PCR. Data show mean ± SD (n = 3/group, measured in triplicate) with *P < 0.05, **P < 0.01, ***P < 0.001 for
AMWAP+ LPS- vs. LPS-treated cells. PBS served as vehicle control.
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acts on the cell surface and predominantly signals via
NFκB, whereas intracellular TLR9 activation mainly stimu-
lates interferon regulatory factors and has only a minor
effect on NFκB targets [38]. BV-2 microglia pretreated with
10 μg/ml AMWAP showed strongly reduced mRNA ex-
pression of IL6, iNOS, CCL2, CASP11, and TNFα after ac-
tivation with the TLR2 ligand zymosan (Figure 4A-E). In
contrast, AMWAP only weakly influenced gene transcrip-
tion of CASP11 triggered by CpG oligodeoxynucleotides as
TLR9 ligands (Figure 4F-J).
To investigate whether exogenous AMWAP is taken up
by microglia and potentially influences NFκB activation,Figure 4 AMWAP reduces TLR2-mediated pro-inflammatory gene transcrip
recombinant AMWAP for 24 h before stimulation with 50 μg/ml zymosan
24 h. The pro-inflammatory marker transcripts IL6 (A, F), iNOS (B, G), CCL2
real-time RT-PCR. Data show mean ± SD (n = 3/group, measured in triplicat
zymosan/CpG-treated cells. PBS served as vehicle control.we treated BV-2 cells with 10 μg/ml fluorescently labeled
AMWAP (AMWAP-Fluo EX) for different time periods.
AMWAP-Fluo EX was gradually incorporated by micro-
glia and ultimately localized to the cytosol in a perinuclear
fashion (Figure 5A-C). Upon stimulation with 50 ng/ml
LPS for 1 h, TLR4-mediated NFκB p65 translocation to
the nucleus was effectively inhibited in AMWAP-positive
cells as shown by quantitative immunocytochemistry
(Figure 5D-G). These findings were confirmed by Western
blot analysis of cytosolic vs. nuclear NFκB p65 levels
for control and AMWAP-treated BV-2 microglia with
or without stimulation with 50 ng/ml LPS for 1 h
(Figure 5H). AMWAP did not interfere with LPS-inducedtion in BV-2 microglia. BV-2 cells were treated with 10 μg/ml of
(A-E) or 4 μg/ml CpG oligodeoxynucleotides (F-J) for additional
(C, H), CASP11 (D, I), and TNFα (E, J) were measured by quantitative
e) with *P < 0.05, **P < 0.01, ***P < 0.001 for AMWAP + zymosan/CpG- vs.
Figure 5 AMWAP is taken up by microglia and inhibits LPS-mediated NFκB activation. (A-C) BV-2 microglia were incubated with fluorescently
labeled recombinant AMWAP (AMWAP-Fluo EX, 10 μg/ml) for 6 and 24 h. Microglia gradually incorporated AMWAP-Fluo EX into their cytosol
exhibiting a perinuclear localization as shown by anti-Iba1 antibody co-staining. (D-G) AMWAP-Fluo EX pretreatment (for 1 to 24 h) time-dependently
inhibited TLR4-mediated nuclear translocation of NFκB p65 after stimulation with 50 ng/ml LPS for 1 h as shown by immunocytochemistry
and quantification of nuclear vs. cytosolic fluorescence intensities. PBS served as vehicle control. Data show mean ± SD (n= 9/group) with *P < 0.05,
**P < 0.01, ***P < 0.001 for AMWAP-treated vs. control cells. (H) Control and AMWAP-treated BV-2 microglia were stimulated with 50 ng/ml LPS for 1 h
and NFκB p65 protein amount was determined in cytosolic (c) and nuclear (n) fractions using Western blot. AMWAP-treated cells exhibited diminished
LPS-triggered NFκB p65 translocation to the nucleus compared to vehicle control. (I) Control and AMWAP-treated BV-2 microglia were stimulated with
50 ng/ml LPS for 1 h and the NFκB p65 phosphorylation status (pNFκB p65) was determined in total cell lysates using Western blot. Actin served as
loading control. Scale bar = 20 μm.
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indicating that AMWAP acts mainly through inhibition of
nuclear NFκB p65 translocation rather than blocking NFκB
p65 phosphorylation. These data are in agreement with ob-
servations from microglia overexpressing AMWAP-GFP,
which showed diminished nuclear NFκB p65 translocation
upon LPS-stimulation (Additional file 1: Figure S1).
AMWAP prevents LPS-triggered degradation of IRAK-1
and IκBα
To further investigate the mechanisms of AMWAP on
microglial NFκB signaling, we analyzed the protein levels
of the NFκB pathway mediators IRAK-1 and IκBα in a
short time course of LPS and AMWAP co-treatment.
Western blot analysis of cytosolic fractions showed a rapid
degradation of both signaling proteins as early as 1 h afterFigure 6 AMWAP prevents LPS-induced degradation of IRAK-1 and IκBα. Con
LPS for 0, 1, 2, and 3 h, and cytosolic protein extracts were prepared. Immuno
level of proteolytic degradation. In AMWAP-treated cells, both signaling molec
was detected after 2 and 3 h in control cells. Actin served as loading control.LPS stimulation of microglia (Figure 6), with apparent
IκBα resynthesis starting after 2 h (Figure 6B). Treatment
with AMWAP effectively protected IRAK-1 and particu-
larly IκBα from rapid LPS-induced proteolysis.
AMWAP acts independent of IκBα phosphorylation,
ubiquitination, or the 20S proteasome
We next assessed the effect of AMWAP on LPS-induced
phosphorylation of IκBα. IκBα phosphorylation is an
upstream event of NFκB p65 nuclear translocation and
thus a critical event in NFκB signaling. BV-2 microglia
were preincubated with the proteasome inhibitor ALLN
(100 μg/ml) for 30 min to allow for accumulation of labile
phosphorylated IκBα species. After stimulation with
50 ng/ml LPS for 30 min, the amount of phosphorylated
IκBα in cytosolic extracts was analyzed using Westerntrol and AMWAP-treated BV-2 microglia were incubated with 50 ng/ml
blot analysis of IRAK-1 (A) and IκBα (B) was carried out to determine the
ules were protected from LPS-induced proteolysis. Resynthesized IκBα
Figure 7 AMWAP does not inhibit IκBα phosphorylation and ubiquitination. (A) Control and AMWAP-treated BV-2 microglia were preincubated
with the proteasome inhibitor ALLN (100 μg/ml) for 30 min to allow for accumulation of phosphorylated IκBα before stimulation with LPS
(50 ng/ml) for 30 min. Levels of phosphorylated IκBα were assessed in cytoplasmic extracts using Western blot analysis. AMWAP did not reduce
LPS-induced IκBα phosphorylation. The presence of various high molecular weight bands was noticed, presumably representing polyubiquitinated,
phosphorylated IκBα. (B) IκBα was immunoprecipitated from cytoplasmic samples of cells treated as in (A). Thereafter, anti-ubiquitin immunoblot
revealed the presence of high molecular weight polyubiquitinated forms of phosphorylated IκBα, which were not diminished in AMWAP-
positive cells. GAPDH served as loading control. (p)IκBα, (phosphorylated) inhibitor of kappa B alpha; Ubi, ubiquitin; IgG, immunoglobulin
G; ALLN; N-acetyl-Leu-Leu-Norleu-al.
Aslanidis et al. Journal of Neuroinflammation  (2015) 12:77 Page 9 of 14blot. Phosphorylated IκBα levels were significantly ele-
vated in LPS-treated cells (Figure 7A). However, this rapid
IκBα phosphorylation was not changed in AMWAP-
treated cells (Figure 7A). In this Western blot, we noticed
the presence of multiple high molecular weight bands,
which presumably represent polyubiquitinated, phosphor-
ylated IκBα-species. To verify this assumption, we immu-
noprecipitated IκBα from the cytoplasmic samples and
carried out anti-ubiquitin immunoblot analysis. This
experiment clearly revealed the presence of high mo-
lecular weight polyubiquitinated forms of phosphory-
lated IκBα between 70 and 130 kDa in LPS-treated
microglia, which were not reduced by AMWAP treatment
(Figure 7B).
Of note, we observed that AMWAP-treated BV-2
microglia accumulated phosphorylated IκBα after stimu-
lation with 50 ng/ml LPS for 30 min even in the absence
of the proteasome inhibitor ALLN and even slightly
inhibited the basal turnover of (phosphorylated) IκBα
under non-LPS-treated conditions (Additional file 2:
Figure S2). These findings prompted us to investigate
whether AMWAP reduces IκBα proteolysis due to
direct inhibition of the 20S proteasome. A luminogenic
cleavage assay using the substrates Z-LRR-aminoluciferin
(for trypsin-like activity), Suc-LLVY-aminoluciferin (for
chymotrypsin-like activity), and Z-nLPnLD-aminoluciferin
(for caspase-like activity) was used to test the three differ-
ent 20S peptidase activities. There was no influence on
20S peptidase activities by AMWAP in contrast to a
strong reduction of all three activities by the proteasome
inhibitor MG-132 (Figure 8). Based on these findings, we
conclude that the AMWAP-triggered inhibition of IκBα
degradation is not mediated by direct interference with
20S proteasome activity.AMWAP induces a neuroprotective microglia phenotype
We next aimed to investigate the effects of recombinant
AMWAP on pro-inflammatory microglial functions in-
cluding the production of toxic oxygen radicals and
direct effects on retinal neurons. As AMWAP significantly
reduced iNOS gene expression in LPS-treated microglia
(Figure 2A, Figure 3B,G), we also tested its influence on
NO production. AMWAP effectively diminished the
strong LPS-induced NO secretion into the microglia cul-
ture supernatant (Figure 9A). To further test the influence
of AMWAP on microglial neurotoxicity, 661W photo-
receptor cells were incubated for 48 h with conditioned
media from BV-2 cells and caspase-related apoptotic cell
death was monitored. 661W photoreceptors cultured in
the presence of microglial supernatants derived from LPS-
activated cells showed higher caspase 3/7 activity, which
was effectively reduced when microglia were treated with
AMWAP (Figure 9B). These data suggest that AMWAP
limits microglial production of neurotoxic molecules and
may potentially induce the release of neurotrophic factors.
As filopodia formation is a hallmark of homeostatic
microglia, we investigated the effect of AMWAP on
microglia morphology. LPS-activated or control BV-2 cells
were cultured in the absence or presence of AMWAP, and
their F-actin cytoskeleton was stained using Phalloidin-
TRITC. AMWAP treatment induced filopodia formation
in control microglia and even reversed the amoeboid
phenotype observed after LPS activation (Figure 10A).
CFSE labeling and FACS analysis demonstrated that
AMWAP did not exert significant anti-mitotic effects on
BV-2 cells, which could have been a potential bias in cell
shape (Figure 10B). We finally analyzed phagocytosis of
cellular debris as another parameter of the non-
inflammatory housekeeping function of microglia. For this
Figure 8 AMWAP does not inhibit peptidase activities of the 20S
proteasome. The effect of recombinant AMWAP (20 μg/ml) on
peptidase activities of the 20S proteasome was assayed using
luminogenic cleavage assays with the substrates Z-LRR-aminoluciferin
(trypsin-like activity) (A), Suc-LLVY-aminoluciferin (chymotrypsin-like
activity) (B), and Z-nLPnLD-aminoluciferin (caspase-like activity) (C). Data
show mean ± SD (n= 4/group) with *P < 0.05, **P < 0.01, ***P < 0.001
for treatment vs. control. MG-132 (1 μM), a potent 20S proteasome
inhibitor, served as a positive control that reduced all three peptidase
activities. PBS served as a vehicle control. MG-132, Z-Leu-Leu-Leu-al.
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fragments were exposed to control and LPS-treated cells
in the absence or presence of AMWAP and the amount of
phagocytosed debris was monitored. AMWAP signifi-
cantly increased the phagocytic uptake of 661W photo-
receptor debris in the presence or absence of LPS,
indicating its important regulatory activity on microglia
(Figure 10C,D).Discussion
We have previously shown that AMWAP overexpression
in microglia induces an anti-inflammatory counter-
regulatory phenotype and that knockdown of AMWAP
leads to higher intrinsic pro-inflammatory cytokine ex-
pression [14]. AMWAP expression and secretion are
themselves controlled by NFκB as blockade of NFκB ac-
tivation inhibits LPS-mediated induction of AMWAP
expression [14]. In the present study, we show that
AMWAP is a secreted protein of reactive microglia that
acts in a paracrine fashion to prevent TLR4- and TLR2-
triggered NFκB translocation. Furthermore, we demon-
strate here that AMWAP interferes with the proteolytic
degradation of the regulator proteins IRAK-1 and IκBα.
This function of AMWAP in microglia is reminiscent of
SLPI, another member of the WAP family, which is se-
creted from macrophages and acts as a suppressor of LPS
responses [39].
To obtain larger amounts of recombinant protein for
further exploration of the immunoregulatory role of
AMWAP, we first generated prokaryotic AMWAP. Since
previous studies on SLPI function demonstrated improved
folding and disulfide bond formation when expressed in
the yeast Pichia pastoris [40,41], we then also obtained
AMWAP from a eukaryotic source. Despite the fact that
both recombinant AMWAP forms used in our study
exerted similar NFκB inhibitory and anti-inflammatory
functions, the risk of LPS contamination is significantly
reduced when using eukaryotic HEK293 EBNA cells for
AMWAP expression.
We showed that AMWAP dampened the TLR4-induced
expression of the bona fide NFκB target genes IL6, iNOS,
CCL2, CASP11, and TNFα in BV-2 microglia, as well
as in ESdM cells, which closely mimic primary micro-
glia regarding their transcriptomic profile [37] and in
mouse brain microglia. We also found that AMWAP
effectively reduced TLR2-mediated pro-inflammatory
gene expression but had only weak effects on TLR9 sig-
naling. TLR2 signals mainly through NFκB, while TLR9
acts predominantly via interferon regulatory factors
(IRFs) [38,42]. Therefore, a plausible explanation for
the lack of AMWAP-mediated inhibition of IL6, iNOS,
CCL2, and TNFα after CpG oligodeoxynucleotide treat-
ment is that these genes are also IRF regulated [43-46]
Figure 9 AMWAP reduces pro-inflammatory microglial nitric oxide production and neurotoxicity on photoreceptor cells. (A) Production of nitric
oxide (NO) as determined by detection of nitrite from BV-2 microglial cells pre-treated with 10 μg/ml AMWAP or vehicle for 24 h before stimulation
with 50 ng/ml LPS for further 24 h. Data show mean ± SD (n = 6/group) with *P < 0.05, **P < 0.01, ***P < 0.001 for AMWAP + LPS vs. LPS-treated cells.
(B) 661W photoreceptor cells were incubated with conditioned media from vehicle-, 10 μg/ml AMWAP-, 50 ng/ml LPS-, and 50 ng/ml LPS + 10 μg/ml
AMWAP-treated BV-2 microglia for 48 h and apoptosis-related caspase 3/7 activity was determined. Data show mean ± SD (n = 5/group) with *P < 0.05,
**P < 0.01, ***P < 0.001 for AMWAP-treated cells vs. control and AMWAP + LPS vs. LPS-treated cells, respectively. PBS served as a vehicle control. NO,
nitric oxide; RLU, relative luciferase units.
Figure 10 AMWAP promotes microglial filopodia formation and phagocytosis. (A) Representative images of Phalloidin-TRITC labeled BV-2
microglial cells pre-treated with 10 μg/ml AMWAP or vehicle for 24 h in the absence or presence of 50 ng/ml LPS for 24 h. (B) CFSE-proliferation assay
of BV-2 microglia treated with 10 μg/ml AMWAP or vehicle for 24 h in the absence or presence of 50 ng/ml LPS for 24 h. The proliferation rate was
assessed 24 h after LPS treatment using flow cytometry and a representative graph out of three repetitions is shown. (C, D) Phagocytosis of
CM-DiI-stained apoptotic 661W photoreceptor debris by BV-2 microglia was monitored and quantified after 6-h feeding time of AMWAP- vs.
vehicle-treated cells in the absence or presence of 50 ng/ml LPS for 24 h. Data show mean ± SD (n = 9/group) with *P < 0.05, **P < 0.01, ***P < 0.001
for AMWAP-treated cells vs. control and AMWAP + LPS vs. LPS-treated cells, respectively. PBS served as a vehicle control. CFSE, carboxyfluorescein
diacetate succinimidyl ester. Scale bar = 20 μm.
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by NFκB and independent from IRFs [47]. These find-
ings are also consistent with data from other whey
acidic proteins as SLPI has been reported to inhibit
TLR2- and TLR4-mediated NFκB activation in human
monocytic U937 cells [48].
Together with our previous observation that AMWAP
inhibits NFκB-dependent CCL2 promoter activity [14],
these findings prompted us to study the direct influence
of AMWAP on microglial NFκB activation. Exogenous
AMWAP was taken up by microglia and effectively
inhibited LPS-triggered nuclear NFκB p65 translocation.
This effect very likely works in an autocrine and para-
crine way as AMWAP is actively secreted from pro-
inflammatory microglia. Upon LPS stimulation, NFκB
p65 is rapidly phosphorylated at Ser536 by IκB kinases
(IKKs) in the cytosol, increasing its transactivation po-
tential once translocated into the nucleus [49]. We did
not observe an inhibition of NFκB p65 phosphorylation
through AMWAP, indicating that the anti-inflammatory
effect of AMWAP is mainly due to cytosolic NFκB re-
tention. We observed a ‘patchy’ perinuclear pattern of
fluorescently labeled AMWAP in the cells, which raised
the question of a possible localization in subcellular
compartments. Interestingly, SLPI is located in cellular
granules in neutrophils and can be released through exo-
cytosis [50]. Another study reported that SLPI partially
resides in the nucleus, where it competes with NFκB for
binding sites at pro-inflammatory gene promoters [51].
However, in this study, we did not observe any nuclear
translocation of fluorescently labeled AMWAP into
microglia, even after prolonged incubation periods.
Our results showed that AMWAP effectively inhib-
ited the rapid LPS-mediated proteolytic degradation of
IRAK-1 and IκBα, concomitantly preventing nuclear
NFκB translocation. Further experiments demonstrated
that IκBα phosphorylation and ubiquitination were not
influenced by AMWAP. This is in agreement with pre-
vious studies reporting similar observations for SLPI
and elafin in monocytes [31,32]. Our experiments also
revealed that AMWAP did not exert direct inhibitory
effects on 20S proteasome activity. In accordance with
our data, the LPS-inducible antibacterial peptide PR39
was shown to block degradation of IκBα without affect-
ing its phosphorylation, ubiquitination, or overall pro-
teasome activity [52]. The anti-bacterial and anti-
protease functions of whey acidic proteins are mainly
attributed to their WAP domains [53-55]. In contrast,
the suppression of the LPS-induced pro-inflammatory
macrophage response mediated by SLPI is independent
of its anti-protease activity [56]. Further analysis will be
required to determine which functional elements in
AMWAP are responsible for its immunomodulatory
function.AMWAP significantly inhibited the LPS-triggered re-
lease of nitric oxide from microglia, an effect that has
been observed in SLPI overexpressing macrophages
[39,56]. AMWAP also reduced microglial neurotoxicity
on 661W photoreceptor cells. In line with this, SLPI has
been shown to reduce LPS-induced neutrophil apoptosis
and a lack of SLPI resulted in increased apoptosis of
myeloid cells [57,58].
Filopodia formation is a hallmark of homeostatic
microglial cells that constantly survey their microenvir-
onment with their branched protrusions [5]. Our experi-
ments indeed showed that AMWAP promotes the
formation of branched filopodia. High phagocytic clear-
ance of apoptotic debris by microglia is also regarded as
an important anti-inflammatory feature [59,60]. We ob-
served an increased phagocytic uptake of apoptotic
photoreceptor fragments by AMWAP-treated microglia,
which was independent of further LPS stimulation as
apoptotic cells per se represent an activating stimulus for
microglia [8]. Along this line, macrophages show elevated
secretion of SLPI during the ingestion of cellular debris,
and a similar effect can be hypothesized for AMWAP and
microglia [61]. Of note, elafin overexpression protects
macrophages from neutrophil elastase-mediated degrad-
ation of their receptors for apoptotic cell recognition,
effectively restoring phagocytic recognition and clearance
in inflammatory settings [62].
Reactive microglia generally exhibit higher prolifera-
tion rates compared to regulatory microglia [9,60]. How-
ever, we were not able to detect any anti-mitotic effect
of AMWAP in BV-2 microglia. It is noteworthy, that
there is conflicting evidence in the literature regarding
the anti-proliferative potential of whey acidic proteins.
One report even observed a SLPI-induced increase of
stem cell proliferation towards an oligodendroglial cell
fate via induction of cyclin D1 [63].
Conclusions
We have shown that AMWAP is a secreted anti-
inflammatory protein of reactive microglia that acts in a
paracrine fashion. Endocytosed AMWAP is localized in a
perinuclear region where it prevents NFκB signaling via
inhibition of IRAK-1 and IκBα proteolytic degradation.
AMWAP does not affect phosphorylation or ubiquitina-
tion of these signaling proteins and has no influence on
overall 20S proteasome activity. On a functional level,
AMWAP inhibits pro-inflammatory gene expression, re-
duces microglial neurotoxicity, promotes filopodia forma-
tion, and increases phagocytic uptake of apoptotic debris.
In conclusion, our data suggest that AMWAP triggers a
neuroprotective phenotype in microglia and that whey
acidic proteins may be potential therapeutics to inhibit a
detrimental microglial phenotype in neurodegenerative
diseases of the brain and retina.
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Additional file 1: Figure S1. AMWAP overexpression reduces LPS-
induced nuclear translocation of NFκB p65. (A) BV-2 microglia overexpressing
AMWAP-GFP and MOCK-GFP control cells were incubated with 50 ng/ml LPS
for 2 h before anti-NFκB immunocytochemistry. AMWAP-GFP overexpressing
cells showed a reduced nuclear translocation of NFκB p65 as shown by
quantification of nuclear and cytosolic fluorescence signals (B) Data show
mean ± SD (n= 9/group) *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar = 20 μm.
Additional file 2: Figure S2. AMWAP inhibits LPS-induced turnover of
(phosphorylated) IκBα. Control and AMWAP-treated BV-2 microglia were
incubated with 50 ng/ml LPS for 30 min, and cytosolic protein extracts
were prepared before immunoblot analysis of phosphorylated IκBα.
LPS-induced IκBα phosphorylation was observed in AMWAP-treated
and control cells. However, AMWAP-treated cells accumulated phosphorylated
IκBα, protecting it from proteasomal degradation and even inhibited the basal
IκBα turnover in unstimulated cells. GAPDH served as loading control. pIκBα,
phosphorylated inhibitor of kappa B alpha.
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